Download PDF
Semin Respir Crit Care Med 2011; 32(3): 328-334
DOI: 10.1055/s-0031-1279829
© Thieme Medical Publishers

Pulmonary-Renal Syndrome with a Focus on Anti-GBM Disease

Jan-Stephan F. Sanders1 , Abraham Rutgers2 , Coen A. Stegeman1 , Cees G.M. Kallenberg2
  • 1Department of Nephrology, University Medical Center Groningen (UMCG), University of Groningen, The Netherlands
  • 2Department of Rheumatology and Clinical Immunology, University Medical Center Groningen (UMCG), University of Groningen, The Netherlands
Further Information

Publication History

Publication Date:
14 June 2011 (online)

    Permissions and Reprints

ABSTRACT

Pulmonary-renal syndrome is a potentially life-threatening combination of pulmonary hemorrhage and acute renal failure. Several pathological entities can cause this syndrome. This review discusses the diagnostic strategy required to initiate appropriate therapy. Rapid serological testing and appropriate interpretation can be of great additive diagnostic value. Also discussed are the pathogenesis, therapy, and outcome of anti–glomerular basement membrane disease, one of the pathological entities that can cause pulmonary-renal syndrome.

KEYWORDS

Anti-GBM - Goodpasture - ANCA - rapidly progressive glomerulonephritis - vasculitis

REFERENCES

  • 1 Goodpasture E W. Landmark publication from the American Journal of the Medical Sciences: the significance of certain pulmonary lesions in relation to the etiology of influenza.  Am J Med Sci. 2009;  338 (2) 148-151
    CrossrefPubMedGoogle Scholar
  • 2 Stanton M C, Tange J D. Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis).  Australas Ann Med. 1958;  7 (2) 132-144
    PubMedGoogle Scholar
  • 3 Lerner R A, Glassock R J, Dixon F J. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis.  J Exp Med. 1967;  126 (6) 989-1004
    CrossrefPubMedGoogle Scholar
  • 4 Gallagher H, Kwan J T, Jayne D R. Pulmonary renal syndrome: a 4-year, single-center experience.  Am J Kidney Dis. 2002;  39 (1) 42-47
    CrossrefPubMedGoogle Scholar
  • 5 Cortese G, Nicali R, Placido R, Gariazzo G, Anrò P. Radiological aspects of diffuse alveolar haemorrhage.  Radiol Med (Torino). 2008;  113 (1) 16-28
    CrossrefPubMedGoogle Scholar
  • 6 Bowley N B, Steiner R E, Chin W S. The chest X-ray in antiglomerular basement membrane antibody disease (Goodpasture's syndrome).  Clin Radiol. 1979;  30 (4) 419-429
    CrossrefPubMedGoogle Scholar
  • 7 Perazella M A, Coca S G, Kanbay M, Brewster U C, Parikh C R. Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients.  Clin J Am Soc Nephrol. 2008;  3 (6) 1615-1619
    CrossrefPubMedGoogle Scholar
  • 8 O'Neill W C. Sonographic evaluation of renal failure.  Am J Kidney Dis. 2000;  35 (6) 1021-1038
    CrossrefPubMedGoogle Scholar
  • 9 Niles J L, Böttinger E P, Saurina G R et al.. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition.  Arch Intern Med. 1996;  156 (4) 440-445
    CrossrefPubMedGoogle Scholar
  • 10 Saxena R, Bygren P, Arvastson B, Wieslander J. Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome.  J Intern Med. 1995;  238 (2) 143-152
    CrossrefPubMedGoogle Scholar
  • 11 Couser W G. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy.  Am J Kidney Dis. 1988;  11 (6) 449-464
    PubMedGoogle Scholar
  • 12 Jennette J C, Falk R J, Andrassy K et al.. Nomenclature of systemic vasculitides. Proposal of an international consensus conference.  Arthritis Rheum. 1994;  37 (2) 187-192
    CrossrefPubMedGoogle Scholar
  • 13 Davies D J, Moran J E, Niall J F, Ryan G B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?.  Br Med J (Clin Res Ed). 1982;  285 (6342) 606
    CrossrefPubMedGoogle Scholar
  • 14 Savige J, Davies D, Falk R J, Jennette J C, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features.  Kidney Int. 2000;  57 (3) 846-862
    CrossrefPubMedGoogle Scholar
  • 15 Savige J, Gillis D, Benson E et al.. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA).  Am J Clin Pathol. 1999;  111 (4) 507-513
    PubMedGoogle Scholar
  • 16 Hagen E C, Daha M R, Hermans J et al.. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.  Kidney Int. 1998;  53 (3) 743-753
    CrossrefPubMedGoogle Scholar
  • 17 Chen M, Kallenberg C G, Zhao M H. ANCA-negative pauci-immune crescentic glomerulonephritis.  Nat Rev Nephrol. 2009;  5 (6) 313-318
    CrossrefPubMedGoogle Scholar
  • 18 Reinhold-Keller E, de Groot K, Holl-Ulrich K et al.. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA): a report of 3 cases and a review of the literature.  Clin Exp Rheumatol. 2001;  19 (5) 541-549
    PubMedGoogle Scholar
  • 19 Jones D A, Jennette J C, Falk R J. Goodpasture's syndrome revisited: a new perspective on glomerulonephritis and alveolar hemorrhage.  N C Med J. 1990;  51 (8) 411-415
    PubMedGoogle Scholar
  • 20 Hudson B G, Kalluri R, Gunwar S, Noelken M E, Mariyama M, Reeders S T. Molecular characteristics of the Goodpasture autoantigen.  Kidney Int. 1993;  43 (1) 135-139
    CrossrefPubMedGoogle Scholar
  • 21 Salama A D, Dougan T, Levy J B et al.. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques.  Am J Kidney Dis. 2002;  39 (6) 1162-1167
    CrossrefPubMedGoogle Scholar
  • 22 Short A K, Esnault V L, Lockwood C M. Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis.  Am J Kidney Dis. 1995;  26 (3) 439-445
    CrossrefPubMedGoogle Scholar
  • 23 Rutgers A, Damoiseaux J, Roozendaal C, Limburg P C, Stegeman C A, Tervaert J W. ANCA-GBM dot-blot: evaluation of an assay in the differential diagnosis of patients presenting with rapidly progressive glomerulonephritis.  J Clin Immunol. 2004;  24 (4) 435-440
    CrossrefPubMedGoogle Scholar
  • 24 Tervaert J W, Damoiseaux J. Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA?.  APMIS Suppl. 2009 June;  (127) 55-59
    PubMedGoogle Scholar
  • 25 Kaul R, Johnson K, Scholz H, Marr G. Performance of the BioPlex 2200 Autoimmune Vasculitis kit.  Autoimmun Rev. 2009;  8 (3) 224-227
    CrossrefPubMedGoogle Scholar
  • 26 Meyers K E, Allen J, Gehret J et al.. Human antiglomerular basement membrane autoantibody disease in XenoMouse II.  Kidney Int. 2002;  61 (5) 1666-1673
    CrossrefPubMedGoogle Scholar
  • 27 Cui Z, Zhao M H. Avidity of anti-glomerular basement membrane autoantibodies was associated with renal pathological damage [in Chinese].  Zhonghua Yi Xue Za Zhi. 2005;  85 (13) 903-907
    PubMedGoogle Scholar
  • 28 Hudson B G, Tryggvason K, Sundaramoorthy M, Neilson E G. Alport's syndrome, Goodpasture's syndrome, and type IV collagen.  N Engl J Med. 2003;  348 (25) 2543-2556
    CrossrefPubMedGoogle Scholar
  • 29 Salama A D, Chaudhry A N, Holthaus K A et al.. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease.  Kidney Int. 2003;  64 (5) 1685-1694
    CrossrefPubMedGoogle Scholar
  • 30 Wu J, Hicks J, Borillo J, Glass II W F, Lou Y H. CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis.  J Clin Invest. 2002;  109 (4) 517-524
    CrossrefPubMedGoogle Scholar
  • 31 Zou J, Hannier S, Cairns L S et al.. Healthy individuals have Goodpasture autoantigen-reactive T cells.  J Am Soc Nephrol. 2008;  19 (2) 396-404
    CrossrefPubMedGoogle Scholar
  • 32 Wolf D, Hochegger K, Wolf A M et al.. CD4+ CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice.  J Am Soc Nephrol. 2005;  16 (5) 1360-1370
    CrossrefPubMedGoogle Scholar
  • 33 Phelps R G, Rees A J. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity.  Kidney Int. 1999;  56 (5) 1638-1653
    CrossrefPubMedGoogle Scholar
  • 34 Johnson J P, Moore Jr J, Austin III H A, Balow J E, Antonovych T T, Wilson C B. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors.  Medicine (Baltimore). 1985;  64 (4) 219-227
    PubMedGoogle Scholar
  • 35 Salama A D, Levy J B, Lightstone L, Pusey C D. Goodpasture's disease.  Lancet. 2001;  358 (9285) 917-920
    CrossrefPubMedGoogle Scholar
  • 36 Levy J B, Turner A N, Rees A J, Pusey C D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.  Ann Intern Med. 2001;  134 (11) 1033-1042
    CrossrefPubMedGoogle Scholar
  • 37 Hirayama K, Yamagata K, Kobayashi M, Koyama A. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan.  Clin Exp Nephrol. 2008;  12 (5) 339-347
    CrossrefPubMedGoogle Scholar
  • 38 Jayne D R, Gaskin G, Rasmussen N European Vasculitis Study Group et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.  J Am Soc Nephrol. 2007;  18 (7) 2180-2188
    CrossrefPubMedGoogle Scholar
  • 39 Laczika K, Knapp S, Derfler K, Soleiman A, Hörl W H, Druml W. Immunoadsorption in Goodpasture's syndrome.  Am J Kidney Dis. 2000;  36 (2) 392-395
    CrossrefPubMedGoogle Scholar
  • 40 Arzoo K, Sadeghi S, Liebman H A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).  Ann Rheum Dis. 2002;  61 (10) 922-924
    CrossrefPubMedGoogle Scholar
  • 41 García-Cantón C, Toledo A, Palomar R et al.. Goodpasture's syndrome treated with mycophenolate mofetil.  Nephrol Dial Transplant. 2000;  15 (6) 920-922
    CrossrefPubMedGoogle Scholar
  • 42 Deegens J K, Artz M A, Hoitsma A J, Wetzels J F. Outcome of renal transplantation in patients with pauci-immune small vessel vasculitis or anti-GBM disease.  Clin Nephrol. 2003;  59 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 43 Cameron J S. Glomerulonephritis in renal transplants.  Transplantation. 1982;  34 (5) 237-245
    CrossrefPubMedGoogle Scholar
  • 44 Sauter M, Schmid H, Anders H J, Heller F, Weiss M, Sitter T. Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy.  Clin Transplant. 2009;  23 (1) 132-136
    CrossrefPubMedGoogle Scholar
  • 45 Khandelwal M, McCormick B B, Lajoie G, Sweet J, Cole E, Cattran D C. Recurrence of anti-GBM disease 8 years after renal transplantation.  Nephrol Dial Transplant. 2004;  19 (2) 491-494
    CrossrefPubMedGoogle Scholar
  • 46 Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert J W. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis.  Am J Kidney Dis. 2005;  46 (2) 253-262
    CrossrefPubMedGoogle Scholar
  • 47 Bosch X, Mirapeix E, Font J et al.. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease.  Clin Nephrol. 1991;  36 (3) 107-113
    PubMedGoogle Scholar
  • 48 Levy J B, Hammad T, Coulthart A, Dougan T, Pusey C D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies.  Kidney Int. 2004;  66 (4) 1535-1540
    CrossrefPubMedGoogle Scholar

Jan-Stephan F SandersM.D. Ph.D. 

Department of Nephrology, University Medical Center Groningen (UMCG), University of Groningen

P.O. Box 30.001, 9700 RB Groningen, The Netherlands

Email: j.sanders@int.umcg.nl

      >